Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

Insight: A Biotech Company That's Going Out of Business

Munchu, which is consensus is about $90 million bucks of revenue this year. They're trying to move it into follicular lymphoma and into first-line B cell lymphoma. And then they have this asset called Pelobrectib, which is a bat inhibitor in development for myelophabrosis. It's an overactive or malignant bone marrow that produces lots of bad cells.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app